NCT02396732

Aspirin and Enoxaparin for VTE in Trauma

The Role Of Combined Therapy With Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if the addition of antiplatelet therapy (i.e. aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of venous thromboembolism (VTE) in high-risk critically injured patients. The investigators further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and enoxaparin for decreasing the incidence of VTE after trauma.

Conditions

• Venous Thromboembolism
• Thromboprophylaxis
• Trauma

Interventions

Type	Name	Description
DRUG	Aspirin	Daily dose is 81 mg oral tablet
DRUG	Enoxaparin	Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.

Timeline

• Start date: 2016-02-01
• Primary completion: 2018-05-15
• Completion: 2018-05-15
• First posted: 2015-03-24
• Last updated: 2019-11-19
• Results posted: 2019-11-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study